Q-omics provides the consensus-scored MYH1 profile across patient tissues and cancer cell-line models. MYH1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYH1 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, MYH1 RNA expression shows 14,834 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, LUAD, and HNSC as cancer lineages where MYH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYH1 survival associations across molecular data types. MYH1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYH1 RNA expression–survival associations across cancer types. High MYH1 expression shows unfavorable associations in ACC, HNSC, LUSC, LAML and THCA, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYH1 RNA expression.
This table summarizes MYH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYH1 shows lower tumor expression in LUAD, BRCA, LUSC, KICH and PRAD and higher tumor expression in LIHC. The LUAD box plot shows higher MYH1 RNA expression in normal versus tumor tissue (log2 FC = −0.409, t-test p < 0.001).
This table shows molecular features associated with MYH1 in patient tissues and cancer cell lines. In patient samples, MYH1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
